Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Side effects associated with intravesical mitomycin.

I Nissenkorn, H Herrod, M S Soloway

    The Journal of Urology
    |November 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Patient tolerability during office cystoscopy and bladder tumor cauterization: a multivariate analysis of risk factors.

    Actas urologicas espanolas·2022
    Same author

    Surveillance and office management of low-grade Ta bladder tumors.

    Actas urologicas espanolas·2022
    Same author

    Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists.

    Prostate cancer and prostatic diseases·2011
    Same author

    Chemotherapy of experimental transitional-cell carcinoma.

    Urology·2011
    Same author

    Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy.

    Prostate cancer and prostatic diseases·2010
    Same author

    Presentation and outcome following radical cystectomy in Hispanics with bladder cancer.

    International braz j urol : official journal of the Brazilian Society of Urology·2008
    Same journal

    On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

    The Journal of urology·2026
    Same journal

    Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

    The Journal of urology·2026
    Same journal

    Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

    The Journal of urology·2026
    Same journal

    The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

    The Journal of urology·2026
    Same journal

    Let's Shift the Focus from Death to Life after Fournier's Gangrene.

    The Journal of urology·2026
    Same journal

    Endourology and Nephrolithiasis.

    The Journal of urology·2026
    See all related articles

    Intravesical chemotherapy with mitomycin C rarely causes systemic toxicity. Most side effects are local, such as moderate cystitis or skin reactions like palmar desquamation, which can be prevented with proper hygiene.

    Area of Science:

    • Oncology
    • Dermatology
    • Urology

    Background:

    • Intravesical chemotherapy is a common treatment for bladder cancer.
    • Mitomycin C is an alkylating agent used in intravesical chemotherapy.
    • Understanding the side effect profile of mitomycin C is crucial for patient management.

    Purpose of the Study:

    • To investigate the nature and severity of side effects associated with intravesical mitomycin C chemotherapy.
    • To identify the incidence of both systemic and local adverse events.
    • To determine potential preventive measures for observed side effects.

    Main Methods:

    • A study was conducted on 29 patients receiving intravesical chemotherapy with mitomycin C.
    • Patients were monitored for systemic and local side effects.

    Related Experiment Videos

  • Skin tests were performed on patients experiencing dermatological reactions.

    • Main Results:

    • No systemic toxicity was reported in any of the 29 patients.
    • Local side effects occurred in 7 patients (24%), including moderate cystitis (3 patients) and drug-related palmar desquamation (4 patients).
    • Three patients were diagnosed with contact dermatitis based on skin tests; one patient developed a generalized rash requiring discontinuation of mitomycin C.

    Conclusions:

    • Intravesical mitomycin C is generally well-tolerated systemically.
    • Local side effects, primarily cystitis and skin reactions, are the main concerns.
    • Implementing careful hand and perineal cleansing post-treatment can mitigate most skin reactions.